This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).
This study will compare how safe and effective sacituzumab tirumotecan is versus thetreatment of physician's choice (TPC) in participants with advanced/metastaticgastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumabtirumotecan is superior to TPC with respect to Overall Survival (OS).
